Wire · operational-macro
FDA Grants Breakthrough Therapy Designation to Enzomenib in R/R KMT2A-Rearranged ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
The FDA has granted breakthrough therapy designation to enzomenib for treating relapsed/refractory acute leukemia with KMT2A rearrangements, allowing expedited review aiming to bring this therapy to patients faster. Enzomenib is an oral small molecule inhibitor targeting the menin-KMT2A interaction, currently in registrational phase 2 trials across multiple global sites.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
FDA's expedited path for enzomenib opens a quicker route to market for menin inhibitors in aggressive leukemia, giving you a rare opening to lead or partner in a niche with high unmet need. Act now to engage with clinical sites or explore combination strategies before others set the standard.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics